Skip to main content
. 2011 Jul 20;14(7):588–592. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2011.07.05

2.

本研究纳入患者疗效评定(n=65)

Efficacy evaluation of patients included in this study (n=65)

Efficacy GO group (n =33) GP group (n =32) P
CR: complete response; PR: partial response; SD: stable disease;
PD: progressive disease; PFS: progression-free survival; OS: overall survival.
CR 0 0
PR 12 13
SD 12 8
PD 9 11
Efficacy 12 (36.4%) 13 (40.6%) 0.801
Clinical stability 24 (72.7%) 21 (65.6%) 0.598
PFS (week) 24 18 0.565
OS (week) 44 36 0.918